Drug Trial Radar · NCT02215512
Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
Last checked: Nov 19, 2026Latest source record: Nov 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Feb 6, 2015
Primary completion
Nov 28, 2016
Study completion Nov 12, 2020
Sponsor
- Lead sponsor
- EpicentRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 13, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this dose-escalation study, the safety and tolerability of escalating dose levels of RRx-001 administered intravenously twice a week in subjects with brain metastases receiving whole brain radiation therapy (WBRT) will be assessed. Once a maximum tolerated dose is identified, further (up to approximately 30) participants will be recruited. The study will use MRI to monitor changes in tumor blood flow associated with RRx-001.
Conditions
- Brain Metastases
Interventions
RRx-001 + WBRTDrug
Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number, frequency and type of adverse eventsTime frame: 42 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Providence Saint John's Health Center
Santa Monica, California
University of Michigan
Ann Arbor, Michigan
Allegiance Health
Jackson, Michigan
Washington University School of Medicine
St Louis, Missouri
The Cancer Institute of New Jersey (Rutgers University)
New Brunswick, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.